Calliditas Provides Patent Update

(MENAFN- PR Newswire) STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT , Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled "New Pharmaceutical Compositions, on January 24, 2024 with validity as of today, February 13, 2024.
This is Calliditas' second patent for TARPEYO in the United States, and provides product protection until 2043.

The patent covers a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name "NEFECON®". Filing for listing in the Orange Book has thus been made.

Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.

"We are delighted with the additional product protection and longer runway until patent expiration with regards to TARPEYO and look forward to successful processes also in other geographies", said CEO Renée Aguiar-Lucander.


For further information, please contact :

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: [email protected]

The information was sent for publication, through the agency of the contact persons set out above, on February 13, 2024 at 17:15 p.m. CET.

The following files are available for download:

Patent PR_ENG

SOURCE Calliditas Therapeutics


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.